摘要
目的:调查血脂异常人群中ApoE基因多态性的分布情况及其对瑞舒伐他汀调脂效果的影响。方法:选取本院2017年1月~2019年6月血脂异常的住院患者127例,采用PCR-荧光探针法测定其ApoE基因型,并分别测定患者服用瑞舒伐他汀钙12周前后的血脂水平进行统计分析。结果:在127例患者中,E3/3基因型比例最高,达62.20%;治疗前E4/4+E3/4基因型的患者TC、TG水平较高且显著高于E3/3基因型(P<0.05);瑞舒伐他汀治疗后各组TC、TG及LDL-C水平均有下降,HDL-C水平均有所提高,其中E3/3基因型的TG水平降低作用最强(P<0.05)。结论:ApoE基因多态性不仅对血脂水平高低有一定的影响,还与瑞舒伐他汀的降脂疗效相关。
Objective:To investigate the distribution of ApoE gene polymorphism in dyslipidemia population and its effect on lipid-lowering effect of rosuvastatin.Methods:A total of 127 inpatients with dyslipidemia in our hospital from January 2017 to June 2019 were selected.ApoE genotype was determined by a PCR-fluorescence probe method.The blood lipid levels of patients before and after taking rosuvastatin calcium for 12 weeks were analyzed.Results:Among the 127 patients,the proportion of E3/3 genotype was the highest,reaching 62.20%.Before treatment,patients with E4/4+E3/4 genotypes had significantly higher TC and TG levels than those with E3/3 genotype(P<0.05).After rosuvastatin treatment,the levels of TC,TG and LDL-C in each group decreased,and the level of HDL-C increased;among them,the TG level of the E3/3 genotype showed the strongest reduction(P<0.05).Conclusion:ApoE gene polymorphism is not only related to the level of blood lipid,but also to the efficacy of rosuvastatin in reducing blood lipid.
作者
杜海燕
缪阳
张婷
卞海林
王兴科
DU Haiyan;MIAO Yang;ZHANG Ting;BIAN Hailin;WANG Xingke(Department of Pharmacy,Yancheng City No.1 Peoples'Hospital,Yancheng,Jiangsu 224000,China)
出处
《药学与临床研究》
2021年第1期47-49,共3页
Pharmaceutical and Clinical Research
基金
江苏省药学会-天晴医院药学基金(Q2018067)。
